Title: | Metabolic dysfunction-associated fatty liver disease and risk of CKD |
Edition: | Original |
Classification: | Experts consensus |
Field: | Comprehensive guideline |
Countries and regions: | China |
Guidelines users: | Clinicians, nurses and technicians engaged in liver disease and renal disease in hospitals |
Evidence classification method: | Grading of recommendations assessment, development and evaluation |
Development unit: | 国际专家小组及 CHESS-MAFLD协作组 |
Registration time: | 2022-06-22 |
Registration number: | IPGRP-2022CN359 |
Purpose of the guideline: | Management and treatments provide a framework for the development of appropriate guidance on CKD in patients with MAFLD |
Latest registration